一种新型抗结核药物表现出强大的临床疗效和良好的安全性:一个开放标签,随机对照,多中心,第二阶段a试验
Naihui Chu1, Wenjuan Nie2, Juan Du3
1Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China. chunaihui1994@sina.com.
Signal transduction and targeted therapy
|December 29, 2025
概括
一种新的结核病药物JDB0131在2a期试验中显示出与德拉曼尼德相比有前途的早期杀菌活性和疗效. 这种新型的胺醇剂为全球结核病负担提供了潜在的新治疗选择.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 结核病 (TB) 仍然是一个重大的全球健康威胁,需要新的治疗策略.
- 现有的治疗方法通常涉及组合化疗,最近的进展包括德拉曼尼德和普雷托曼尼德等尼特罗伊米达剂.
- JDB0131代表了第三代胺醇剂,旨在改进早期化合物.
研究的目的:
- 评估新型抗结核剂JDB0131在新确诊结核病患者中的疗效和安全性.
- 为了比较JDB0131的早期杀菌活性 (EBA) 和整体疗效与德拉曼尼德和标准疗法.
- 通过不良事件监测评估JDB0131的安全概况.
主要方法:
- 一个多中心,前性,随机的2a期试验,涉及52名新诊断的结核病患者.
- 用JDB0131 (100 mg bid, 200 mg qd, 200 mg bid) 的剂量升级与德拉曼尼德 (100 mg bid) 和固定剂量组合 (FDC) 方案作为对照.
- 主要终点:结核病殖民地形成单位 (log10 CFU) 的对数变化;次要终点包括时间到阳性 (TTP) 和不良事件 (AE).
主要成果:
- 与德拉曼尼德相比,JDB0131表现出优越的早期杀菌活性 (EBA).
- 在0至14天之间,JDB0131的最高剂量 (200毫克两次) 显示出比德拉曼尼德更高的疗效.
- 在第14天,所有JDB0131剂量水平与德拉曼尼德相比,都实现了较高的阳性时间 (TTP).
- 在接受JDB0131.1治疗的30名患者中报告了91例非严重不良事件.
结论:
- 在新确诊结核病的患者中,JDB0131表现出有希望的疗效和有利的早期杀菌活性.
- 新型尼特罗伊米达剂JDB0131代表了一种潜在的新疗法选择,以解决全球结核病负担.
- 鉴于其改善结核病治疗结果的潜力,对JDB0131的进一步调查是有必要的.
更多相关视频
相关概念视频
01:28Pulmonary Tuberculosis V
520
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
520
01:28Pulmonary Tuberculosis II
1.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.3K
01:26Pulmonary Tuberculosis IV
467
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
467
01:29Pulmonary Tuberculosis I
801
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
801
01:31Pulmonary Tuberculosis III
884
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
884
01:11Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K